BBP
Virtus LifeSci Biotech Products ETF
Set alert
104.18 USD -1.08 -1.03%
103.66 Day range 105.27
73.00 52-week range 109.90
- YTD
- +30.36%
- 1 year
- +42.52%
- Open
- 105.03
- Prev close
- 105.26
- Mkt cap
- 42.83M
- Vol
- 12.34K
- Avg vol
- 12.14K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 103.66
- High
- 105.27
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 63.72
- 200-d avg
- 60.18
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 63.72
- 200-day average
- 60.18
About Virtus LifeSci Biotech Products ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
News
- ETFs That You May Consider Amid a Strengthening Biotech Outlook
- BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
- Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
- BBP: The Biotech ETF That Filters For FDA-Approved Drugs
- BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
- ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
- BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
- ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check
- ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use
- Why Is ImmunityBio Stock Soaring On Friday?
Your note
Sign in to keep a note on BBP — it syncs with the Stock Master app.